Results of weekday-on and weekend-off administration schedule of sunitinib therapy for advanced renal cell carcinoma

Kawashima, Atsunari; Uemura, Mamoru; Kato, Taigo; Ujike, Takeshi; Nagahara, Akira; Fujita, Kazutoshi; Imamura, Ryoichi; Yamanaka, Yohei; Tomiyama, Eisuke; Tanigawa, Go; Miyagawa, Yasushi; Yoshioka, Toshiaki; Miyake, Osamu; Nonomura, Norio

doi:10.1007/s10147-018-1332-1

Cited by 3 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The dose intensity correlated with anti-cancer effects induced by multiple types of anti-cancer agents used for malignancies. Continuing sunitinib therapy for more than one course and maintaining more than 60% of 1-month RDI correlated with better outcome for progression-free survival in patients with metastatic RCC (34). Similarly, more than 65% of two course-RDI should be maintained for optimal therapeutic efficacy of sunitinib treatment (35).…”

Section: Discussionmentioning

confidence: 96%

Oral intake of royal jelly improves anti‑cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF‑α and TGF‑β in renal cell carcinoma: A preliminary study based on a randomized double‑blind clinical trial

et al. 2020

View full text Add to dashboard Cite

Molecular targeted therapies are commonly used in patients with metastatic renal cell carcinoma (RCC). However, the efficacy and safety of these therapeutic interventions require enhancement to improve prognosis in these patients. Royal jelly (RJ) has anti-cancer effects and adverse events across a variety of types of malignancy. The present study investigated the detailed mechanism underlying the effects of oral administration of RJ in patients with advanced RCC that were treated with molecular targeted agents in a randomized clinical trial. The study cohort comprised 16 patients treated with RJ and 17 patients treated with a placebo. Serum levels of tumor necrosis factor (TNF)-α and transforming growth factor (TGF)-β were measured using enzyme-linked immunosorbent assays. The results of the present study demonstrated a larger decrease in tumor size upon supplementing patients with RJ following molecular targeted therapy compared with that in patients administered with the placebo. Patients exhibited reduced anorexia and fatigue in the RJ group compared with the placebo group. The relative dose intensity for patients in the RJ group was higher than that in patients in the placebo group. Post-and pre-treatment ratios of the serum levels of TNF-α and TGF-β in patients in the RJ group were lower than those in patients in the placebo group, and these ratios correlated with decreasing tumor size and frequency of anorexia or fatigue in patients. In conclusion, the results of the present study indicated that oral intake of RJ improved the efficacy and safety of molecular targeted therapy in patients with RCC and changed the levels of TNF-α and TGF-β in the serum of patients, which is speculated to serve an important role in RJ-induced biological activities.

show abstract

Section: Discussionmentioning

confidence: 96%

Oral intake of royal jelly improves anti‑cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF‑α and TGF‑β in renal cell carcinoma: A preliminary study based on a randomized double‑blind clinical trial

et al. 2020

View full text Add to dashboard Cite

show abstract

Comparison of axitinib and sunitinib as first-line therapies for metastatic renal cell carcinoma: a real-world multicenter analysis

et al. 2018

View full text Add to dashboard Cite

[Corrigendum] Oral intake of royal jelly improves anti‑cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF‑α and TGF‑β in renal cell carcinoma: A preliminary study based on a randomized double‑blind clinical trial

et al. 2020

View full text Add to dashboard Cite

Results of weekday-on and weekend-off administration schedule of sunitinib therapy for advanced renal cell carcinoma

Abstract: We report the results of an alternative medication schedule, the "weekday-on and weekend-off regimen", as a means of increasing 6W-RDI for metastatic RCC patients.

Cited by 3 publications

References 26 publications

Oral intake of royal jelly improves anti‑cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF‑α and TGF‑β in renal cell carcinoma: A preliminary study based on a randomized double‑blind clinical trial

Oral intake of royal jelly improves anti‑cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF‑α and TGF‑β in renal cell carcinoma: A preliminary study based on a randomized double‑blind clinical trial

Comparison of axitinib and sunitinib as first-line therapies for metastatic renal cell carcinoma: a real-world multicenter analysis

[Corrigendum] Oral intake of royal jelly improves anti‑cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF‑α and TGF‑β in renal cell carcinoma: A preliminary study based on a randomized double‑blind clinical trial

Contact Info

Product

Resources

About

Results of weekday-on and weekend-off administration schedule of sunitinib therapy for advanced renal cell carcinoma

Abstract: We report the results of an alternative medication schedule, the "weekday-on and weekend-off regimen", as a means of increasing 6W-RDI for metastatic RCC patients.

Cited by 3 publications

References 26 publications

Oral intake of royal jelly improves anti‑cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF‑&alpha; and TGF‑&beta; in renal cell carcinoma: A preliminary study based on a randomized double‑blind clinical trial

Oral intake of royal jelly improves anti‑cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF‑&alpha; and TGF‑&beta; in renal cell carcinoma: A preliminary study based on a randomized double‑blind clinical trial

Comparison of axitinib and sunitinib as first-line therapies for metastatic renal cell carcinoma: a real-world multicenter analysis

[Corrigendum] Oral intake of royal jelly improves anti‑cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF‑&alpha; and TGF‑&beta; in renal cell carcinoma: A preliminary study based on a randomized double‑blind clinical trial

Contact Info

Product

Resources

About

Oral intake of royal jelly improves anti‑cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF‑α and TGF‑β in renal cell carcinoma: A preliminary study based on a randomized double‑blind clinical trial

Oral intake of royal jelly improves anti‑cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF‑α and TGF‑β in renal cell carcinoma: A preliminary study based on a randomized double‑blind clinical trial

[Corrigendum] Oral intake of royal jelly improves anti‑cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF‑α and TGF‑β in renal cell carcinoma: A preliminary study based on a randomized double‑blind clinical trial